Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1994 Apr;93(4):1473–1480. doi: 10.1172/JCI117125

A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan).

R M Silver 1, A Ludwicka 1, M Hampton 1, T Ohba 1, S A Bingel 1, T Smith 1, R A Harley 1, J Maize 1, M P Heyes 1
PMCID: PMC294161  PMID: 8163652

Abstract

The eosinophilia-myalgia syndrome (EMS) is a recently described disease that has been associated with the ingestion of L-tryptophan containing trace amounts of several impurities. The first such contaminant to be identified and linked epidemiologically to the EMS epidemic was 1,1'-ethylidenebis(L-tryptophan) (EBT), but its role in the etiology and pathogenesis of the syndrome has been controversial. We report the development of inflammation and fibrosis affecting the dermis and subcutis, including the fascia and perimyseal tissues, after the daily intraperitoneal administration of EBT to female C57BL/6 mice. Such changes are accompanied by increased numbers of mast cells, many of which appear to be degranulating. Plasma levels of quinolinic acid, a metabolic product of L-tryptophan via the kynurenine pathway, are reduced initially, and then become elevated when inflammation and fibrosis are more pronounced. The nature and location of the inflammatory cell infiltrate and fibrosis, as well as the presence of mast cells and alterations of L-tryptophan metabolism, are consistent with findings reported in patients with EMS. This murine model suggests that EBT may have been one of the mediators of EMS and should facilitate studies of the pathogenesis of EMS.

Full text

PDF
1480

Images in this article

1474Image
on p.1474
1477Image
on p.1477

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auerbach S. B., Falk H. Eosinophilia-myalgia syndrome: CDC update. Cleve Clin J Med. 1991 May-Jun;58(3):215–217. doi: 10.3949/ccjm.58.3.215. [DOI] [PubMed] [Google Scholar]
  2. Belongia E. A., Hedberg C. W., Gleich G. J., White K. E., Mayeno A. N., Loegering D. A., Dunnette S. L., Pirie P. L., MacDonald K. L., Osterholm M. T. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med. 1990 Aug 9;323(6):357–365. doi: 10.1056/NEJM199008093230601. [DOI] [PubMed] [Google Scholar]
  3. Boucek R. J., Alvarez T. R. 5-hydroxytryptamine: a cytospecific growth stimulator of cultured fibroblasts. Science. 1970 Feb 6;167(3919):898–899. doi: 10.1126/science.167.3919.898. [DOI] [PubMed] [Google Scholar]
  4. Bulpitt K. J., Verity M. A., Clements P. J., Paulus H. E. Association of L-tryptophan and an illness resembling eosinophilic fasciitis. Clinical and histopathologic findings in four patients with eosinophilia-myalgia syndrome. Arthritis Rheum. 1990 Jul;33(7):918–929. doi: 10.1002/art.1780330702. [DOI] [PubMed] [Google Scholar]
  5. Claman H. N., Choi K. L., Sujansky W., Vatter A. E. Mast cell "disappearance" in chronic murine graft-vs-host disease (GVHD)-ultrastructural demonstration of "phantom mast cells". J Immunol. 1986 Sep 15;137(6):2009–2013. [PubMed] [Google Scholar]
  6. Claman H. N., Jaffee B. D., Huff J. C., Clark R. A. Chronic graft-versus-host disease as a model for scleroderma. II. Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. Cell Immunol. 1985 Aug;94(1):73–84. doi: 10.1016/0008-8749(85)90086-3. [DOI] [PubMed] [Google Scholar]
  7. Claman H. N. Mast cell depletion in murine chronic graft-versus-host disease. J Invest Dermatol. 1985 Apr;84(4):246–248. doi: 10.1111/1523-1747.ep12265302. [DOI] [PubMed] [Google Scholar]
  8. Clauw D. J., Nashel D. J., Umhau A., Katz P. Tryptophan-associated eosinophilic connective-tissue disease. A new clinical entity? JAMA. 1990 Mar 16;263(11):1502–1506. [PubMed] [Google Scholar]
  9. Crofford L. J., Rader J. I., Dalakas M. C., Hill R. H., Jr, Page S. W., Needham L. L., Brady L. S., Heyes M. P., Wilder R. L., Gold P. W. L-tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat. J Clin Invest. 1990 Nov;86(5):1757–1763. doi: 10.1172/JCI114902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. DeSchryver-Kecskemeti K., Gramlich T. L., Crofford L. J., Rader J. I., Page S. W., Needham L. L., Hill R. H., Jr, Sternberg E. M. Environmental pathology. Mast cell and eosinophil infiltration in intestinal mucosa of Lewis rats treated with L-tryptophan implicated in human eosinophilia myalgia syndrome. Mod Pathol. 1991 May;4(3):354–357. [PubMed] [Google Scholar]
  11. Driskell W. J., Ashley D. L., Grainger J., Sirimanne S. R., Mazzola E. P., Page S. W., Needham L. L., Hill R. H., Jr Identification of decomposition products of 1,1'-ethylidenebis [L-tryptophan], a compound associated with eosinophilia-myalgia syndrome. Bull Environ Contam Toxicol. 1992 May;48(5):679–687. doi: 10.1007/BF00195987. [DOI] [PubMed] [Google Scholar]
  12. Fonseca E., Solís J. Mast cells in the skin: progressive systemic sclerosis and the toxic oil syndrome. Ann Intern Med. 1985 Jun;102(6):864–865. doi: 10.7326/0003-4819-102-6-864_2. [DOI] [PubMed] [Google Scholar]
  13. Hawkins R. A., Claman H. N., Clark R. A., Steigerwald J. C. Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? Ann Intern Med. 1985 Feb;102(2):182–186. doi: 10.7326/0003-4819-102-2-182. [DOI] [PubMed] [Google Scholar]
  14. Heiman-Patterson T. D., Bird S. J., Parry G. J., Varga J., Shy M. E., Culligan N. W., Edelsohn L., Tatarian G. T., Heyes M. P., Garcia C. A. Peripheral neuropathy associated with eosinophilia-myalgia syndrome. Ann Neurol. 1990 Oct;28(4):522–528. doi: 10.1002/ana.410280409. [DOI] [PubMed] [Google Scholar]
  15. Hertzman P. A., Blevins W. L., Mayer J., Greenfield B., Ting M., Gleich G. J. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med. 1990 Mar 29;322(13):869–873. doi: 10.1056/NEJM199003293221301. [DOI] [PubMed] [Google Scholar]
  16. Heyes M. P., Markey S. P. Quantification of quinolinic acid in rat brain, whole blood, and plasma by gas chromatography and negative chemical ionization mass spectrometry: effects of systemic L-tryptophan administration on brain and blood quinolinic acid concentrations. Anal Biochem. 1988 Oct;174(1):349–359. doi: 10.1016/0003-2697(88)90556-8. [DOI] [PubMed] [Google Scholar]
  17. Ito J., Hosaki Y., Torigoe Y., Sakimoto K. Identification of substances formed by decomposition of peak E substance in tryptophan. Food Chem Toxicol. 1992 Jan;30(1):71–81. doi: 10.1016/0278-6915(92)90139-c. [DOI] [PubMed] [Google Scholar]
  18. Kamb M. L., Murphy J. J., Jones J. L., Caston J. C., Nederlof K., Horney L. F., Swygert L. A., Falk H., Kilbourne E. M. Eosinophilia-myalgia syndrome in L-tryptophan-exposed patients. JAMA. 1992 Jan 1;267(1):77–82. doi: 10.1001/jama.267.1.77. [DOI] [PubMed] [Google Scholar]
  19. Kaufman L. D., Seidman R. J., Gruber B. L. L-tryptophan-associated eosinophilic perimyositis, neuritis, and fasciitis. A clinicopathologic and laboratory study of 25 patients. Medicine (Baltimore) 1990 Jul;69(4):187–199. doi: 10.1097/00005792-199007000-00001. [DOI] [PubMed] [Google Scholar]
  20. Kaufman L. D., Seidman R. J., Phillips M. E., Gruber B. L. Cutaneous manifestations of the L-tryptophan-associated eosinophilia-myalgia syndrome: a spectrum of sclerodermatous skin disease. J Am Acad Dermatol. 1990 Dec;23(6 Pt 1):1063–1069. doi: 10.1016/0190-9622(90)70334-e. [DOI] [PubMed] [Google Scholar]
  21. Kilbourne E. M., Posada de la Paz M., Abaitua Borda I., Diez Ruiz-Navarro M., Philen R. M., Falk H. Toxic oil syndrome: a current clinical and epidemiologic summary, including comparisons with the eosinophilia-myalgia syndrome. J Am Coll Cardiol. 1991 Sep;18(3):711–717. doi: 10.1016/0735-1097(91)90794-a. [DOI] [PubMed] [Google Scholar]
  22. Kilbourne E. M., Posada de la Paz M., Abaitua Borda I. Epidemiological studies. WHO Reg Publ Eur Ser. 1992;42:5–25. [PubMed] [Google Scholar]
  23. Kilbourne E. M., Swygert L. A., Philen R. M., Sun R. K., Auerbach S. B., Miller L., Nelson D. E., Falk H. Interim guidance on the eosinophilia-myalgia syndrome. Ann Intern Med. 1990 Jan 15;112(2):85–87. doi: 10.7326/0003-4819-112-2-85. [DOI] [PubMed] [Google Scholar]
  24. LEDER L. D. UBER DIE SELEKTIVE FERMENTCYTOCHEMISCHE DARSTELLUNG VON NEUTROPHILEN MYELOISCHEN ZELLEN UND GEWEBSMASTZELLEN IM PARAFFINSCHNITT. Klin Wochenschr. 1964 Jun 1;42:553–553. doi: 10.1007/BF01486688. [DOI] [PubMed] [Google Scholar]
  25. Love L. A., Rader J. I., Crofford L. J., Raybourne R. B., Principato M. A., Page S. W., Trucksess M. W., Smith M. J., Dugan E. M., Turner M. L. Pathological and immunological effects of ingesting L-tryptophan and 1,1'-ethylidenebis (L-tryptophan) in Lewis rats. J Clin Invest. 1993 Mar;91(3):804–811. doi: 10.1172/JCI116300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. MACDONALD R. A., ROBBINS S. L., MALLORY G. K. Dermal fibrosis following subcutaneous injections of serotonin creatinine sulphate. Proc Soc Exp Biol Med. 1958 Feb;97(2):334–337. doi: 10.3181/00379727-97-23734. [DOI] [PubMed] [Google Scholar]
  27. Madara J. L., Carlson S. Supraphysiologic L-tryptophan elicits cytoskeletal and macromolecular permeability alterations in hamster small intestinal epithelium in vitro. J Clin Invest. 1991 Feb;87(2):454–462. doi: 10.1172/JCI115017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Mayeno A. N., Belongia E. A., Lin F., Lundy S. K., Gleich G. J. 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome? Mayo Clin Proc. 1992 Dec;67(12):1134–1139. doi: 10.1016/s0025-6196(12)61142-2. [DOI] [PubMed] [Google Scholar]
  29. Mayeno A. N., Lin F., Foote C. S., Loegering D. A., Ames M. M., Hedberg C. W., Gleich G. J. Characterization of "peak E," a novel amino acid associated with eosinophilia-myalgia syndrome. Science. 1990 Dec 21;250(4988):1707–1708. doi: 10.1126/science.2270484. [DOI] [PubMed] [Google Scholar]
  30. Ozaki Y., Edelstein M. P., Duch D. S. The actions of interferon and antiinflammatory agents of induction of indoleamine 2,3-dioxygenase in human peripheral blood monocytes. Biochem Biophys Res Commun. 1987 May 14;144(3):1147–1153. doi: 10.1016/0006-291x(87)91431-8. [DOI] [PubMed] [Google Scholar]
  31. Peltonen J., Varga J., Sollberg S., Uitto J., Jimenez S. A. Elevated expression of the genes for transforming growth factor-beta 1 and type VI collagen in diffuse fasciitis associated with the eosinophilia-myalgia syndrome. J Invest Dermatol. 1991 Jan;96(1):20–25. doi: 10.1111/1523-1747.ep12514683. [DOI] [PubMed] [Google Scholar]
  32. Read C. A., Clauw D., Weir C., Da Silva A. T., Katz P. Dyspnea and pulmonary function in the L-tryptophan-associated eosinophilia-myalgia syndrome. Chest. 1992 May;101(5):1282–1286. doi: 10.1378/chest.101.5.1282. [DOI] [PubMed] [Google Scholar]
  33. Seuwen K., Magnaldo I., Pouysségur J. Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein. Nature. 1988 Sep 15;335(6187):254–256. doi: 10.1038/335254a0. [DOI] [PubMed] [Google Scholar]
  34. Sidransky H., Verney E., Cosgrove J. W., Schwartz A. M. Studies with compounds that compete with tryptophan binding to rat hepatic nuclei. J Nutr. 1992 May;122(5):1085–1095. doi: 10.1093/jn/122.5.1085. [DOI] [PubMed] [Google Scholar]
  35. Silver R. M., Heyes M. P., Maize J. C., Quearry B., Vionnet-Fuasset M., Sternberg E. M. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med. 1990 Mar 29;322(13):874–881. doi: 10.1056/NEJM199003293221302. [DOI] [PubMed] [Google Scholar]
  36. Silver R. M., McKinley K., Smith E. A., Quearry B., Harati Y., Sternberg E. M., Heyes M. P. Tryptophan metabolism via the kynurenine pathway in patients with the eosinophilia-myalgia syndrome. Arthritis Rheum. 1992 Sep;35(9):1097–1105. doi: 10.1002/art.1780350916. [DOI] [PubMed] [Google Scholar]
  37. Slutsker L., Hoesly F. C., Miller L., Williams L. P., Watson J. C., Fleming D. W. Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer. JAMA. 1990 Jul 11;264(2):213–217. [PubMed] [Google Scholar]
  38. Smith B. E., Dyck P. J. Peripheral neuropathy in the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Neurology. 1990 Jul;40(7):1035–1040. doi: 10.1212/wnl.40.7.1035. [DOI] [PubMed] [Google Scholar]
  39. Varga J., Peltonen J., Uitto J., Jimenez S. Development of diffuse fasciitis with eosinophilia during L-tryptophan treatment: demonstration of elevated type I collagen gene expression in affected tissues. A clinicopathologic study of four patients. Ann Intern Med. 1990 Mar 1;112(5):344–351. doi: 10.7326/0003-4819-112-5-344. [DOI] [PubMed] [Google Scholar]
  40. Vázquez Roncero A., Janer del Valle C., Maestro Durán R., Graciani Constante E. New aniline derivatives in cooking oils associated with toxic oil syndrome. Lancet. 1983 Oct 29;2(8357):1024–1025. doi: 10.1016/s0140-6736(83)91005-x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES